Back to search

Article

A physiologically-based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activity

2024-01-31

Abstract excerpt

Aims CYP2C19 activity is associated with treatment response to clopidogrel through the formation of the active H4 metabolite. The aims of this study were to develop a physiologically-based pharmacokinetic (PBPK) model of clopidogrel and its metabolites for populations of European ancestry, to predict pharmacokinetics in the Japanese population by CYP2C19 phenotype (extensive metaboliser, EM; intermediate metabolis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
df4d8020-646c-59d9-b1ff-c2e8237f3e7b
DOI
10.22541/au.170668953.37059673/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A physiologically-based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: an evaluation of CYP2C19 activityDOI 10.22541/au.170668953.37059673/v1
Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.Semantic proximity
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.Semantic proximity
Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.Semantic proximity
Clopidogrel pharmacogenetics: metabolism and drug interactions.Semantic proximity
Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects.Semantic proximity
Adverse events in cardiovascular disease patients taking clopidogrel: impact of CYP2C19 genotype polymorphismsSemantic proximity
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.Semantic proximity
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular MedicineSemantic proximity
[Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].Semantic proximity
A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.Semantic proximity
Influence of CYP2C19 and ABCB1 Genetic Polymorphisms on Clopidogrel Pharmacokinetics: A PharmGKB Retrospective AnalysisSemantic proximity
Impact of CYP2C19 polymorphism and proton pump inhibitors on platelet reactivity to clopidogrel and clinical outcomes following stent implantation.Semantic proximity
Select a neighboring publication to make it the new centre.